FOLH1 and neoplasm: The theoretical, deferred-to-later-in-life risk can be considered secondary in view of the gain in both lifespan and quality of life achieved through timely, customized, patient-centric therapy based on tumor lesions diagnosed with Zr-89-labeled PSMA ligands, which might have been overlooked with shorter-lived tracers.